Journal Mobile Options
Table of Contents
Vol. 31, No. 4, 2008
Issue release date: April 2008
Onkologie 2008;31:185–189

A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Görn M. · Habermann C.R. · Anige M. · Thöm I. · Schuch G. · Andritzky B. · Brandl S. · Burkholder I. · Edler L. · Hossfeld D.K. · Bokemeyer C. · Laack E.
a Department of Oncology, Hematology, Bone Marrow Transplantation with the Section of Pneumology, bDepartment for Interventional and Diagnostic Radiology, University Hospital Hamburg-Eppendorf, Hamburg, c Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The aim of this pilot study was to evaluate the efficacy and safety of a chemotherapy containing docetaxel and oral trofosfamide as a ‘metronomic’ secondline treatment of patients with metastatic non-small cell lung cancer (NSCLC). Patients and Methods: 21 patients with stage IV disease NSCLC who had progressed under first-line chemotherapy were enrolled. Previous chemotherapy was platinum-based in 15 patients (71.4%), whereas 6 patients (28.6%) had received platinum-free combination chemotherapy. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15 every 4 weeks plus trofosfamide 50 mg per day. Results: A total of 62 chemotherapy cycles were administered. The median number of cycles per patient was 3. The overall response rate to chemotherapy was 19%, median overall survival was 6.9 months, the median progression-free survival 2.9 months, the 1-year survival rate 28.6%, and the 2-year survival rate 7.1%. No grade IV toxicity was observed. Conclusions: Our results suggest that the combination of docetaxel and trofosfamide in a metronomic schedule is active and well tolerable as second-line therapy in patients with metastatic NSCLC. The concept of metronomic chemotherapy promises to be a valuable addition to the existing treatment options in NSCLC and warrants further investigation in phase III studies.

 goto top of outline Author Contacts

Dr. med. Michael Görn, Innovation Onkologie Research & Consulting, Lerchenfeld 14, 22081 Hamburg, Germany, Tel. +49 40 226046-46, Fax -51, E-mail

 goto top of outline Article Information

Published online: March 20, 2008
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 0, Number of References : 0

 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 31, No. 4, Year 2008 (Cover Date: April 2008)

Journal Editor: Schmoll H.-J. (Halle)
ISSN: 0378–584X (Print), eISSN: 1423–0240 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50